HealthInvest Partners’s Zevra Therapeutics ZVRA Stock Holding History

HealthInvest Partners’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$1.51M	Sell	330,000 -420,000	-56%	-$2.13M	2.92%	9
2022 Q3	$4.68M	Buy	750,000 +80,000	+12%	+$453K	9.89%	5
2022 Q2	$2.99M	Buy	670,000 +415,000	+163%	+$1.89M	6.89%	10
2022 Q1	$1.28M	Buy	+255,000	New	+$1.62M	2.04%	11

Other funds holding ZVRA

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RPCONE

Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return

MAM

Mystic Asset Management Warwick, Rhode Island $431M AUM 25.35% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HealthInvest Partners's ZVRA Position: Q4 2022 in Review

HealthInvest Partners reduced its Zevra Therapeutics (ZVRA) stake by 56% in Q4 2022, selling an estimated $2.13M and leaving 330,000 shares worth $1.51M. The position accounts for 2.92% of the portfolio, ranked #9.

HealthInvest Partners first reported a position in ZVRA in Q1 2022 and has held it in 4 quarters since. The position peaked at $4.68M in Q3 2022. 70 funds tracked by Wall St. Rank hold ZVRA as of Q4 2022.

HealthInvest Partners held 330,000 shares of Zevra Therapeutics worth $1.51M as of Q4 2022.
HealthInvest Partners sold 420,000 Zevra Therapeutics shares in Q4 2022, an estimated $2.13M.
Zevra Therapeutics made up 2.92% of HealthInvest Partners's portfolio in Q4 2022, its #9 holding.
HealthInvest Partners first reported a position in Zevra Therapeutics in Q1 2022 and has held it in 4 quarters since.
HealthInvest Partners's Zevra Therapeutics position peaked at $4.68M in Q3 2022.
70 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2022.

Based on HealthInvest Partners's 13F filing for Q4 2022, filed 14 Feb 2023.